Hims & Hers shares fell 15% after first-quarter earnings miss. Company posted a surprise loss tied to GLP-1 restructuring ...
Stocktwits on MSN
HIMS stock on the mend? New testosterone push builds as GLP-1 gold rush gets crowded
The company launched Testosterone Rx+, a once-daily pill designed to help the body naturally increase testosterone levels. ・The rollout follows a recent FDA order supporting expanded testosterone ...
Add Yahoo as a preferred source to see more of our stories on Google. Hims & Hers will now sell only the cheaper weight loss drugs at a limited scale, the company says. (Hims and Hers) Hims & Hers had ...
The FDA said it plans to restrict GLP-1 ingredients used in compounded drugs that companies such as Hims and online ...
Asianet Newsable on MSN
HIMS stock plunges 10% after hours: FDA chief warns of 'swift action' on copycat drugs after Novo semaglutide knockoff launch
The stock decline also follows the FDA's flagging of safety and quality risks in non-approved GLP-1 drugs.
Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop ...
Novo Nordisk and Hims & Hers have ended a legal feud with an agreement that allows the telehealth platform to sell the pharma giant’s blockbuster brand-name GLP-1 drugs. In separate statements issued ...
Thu, March 12, 2026 at 2:46 PM UTC Then came the surprise truce announced last Friday: Novo dropped the lawsuit (while reserving the right to refile), and Hims agreed to sell branded Wegovy and ...
May 11 (Reuters) - Hims & Hers Health raised its 2026 revenue forecast on Monday, betting on increased sales for its ...
Hims & Hers Health stock has been recovering from a drawdown earlier this year, as regulatory and legal risks surrounding the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results